Welcome to our dedicated page for InspireMD news (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on InspireMD stock.
InspireMD, Inc. (NASDAQ: NSPR), located at 800 Boylston Street, Suite 16041, Boston, Massachusetts, is a pioneering medical device company. It specializes in the development and commercialization of its proprietary MicroNet stent platform technology, which addresses complex vascular and coronary diseases. The company's flagship products include the CGuard Carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS).
The CGuard EPS, which integrates MicroNet technology with a self-expandable nitinol stent, is primarily used for carotid artery applications and is a significant revenue driver for the company. InspireMD operates globally, with key markets in Italy, Germany, Russia, among others.
In a recent move, InspireMD has focused on expanding its intellectual property portfolio to support its strategic direction. October 2023 saw the Centers for Medicare and Medicaid Services (CMS) expand coverage for carotid artery stenting, including asymptomatic and standard-risk patients. This development is expected to enhance the adoption of InspireMD's products.
Additionally, in the third quarter of 2023, InspireMD reported its financial results and ongoing projects. They are currently enrolling patients in a study to investigate the safety and feasibility of using CGuard EPS for treating acute ischemic stroke patients with tandem lesions. This study is expected to enroll 15 patients across three U.S. sites.
CEO Marvin Slosman emphasized the importance of this study in addressing carotid lesions in acute stroke settings, marking a crucial step in their long-term growth strategy. The company also continues its work on the Premarket Approval Application (PMA) for the C-GUARDIANS U.S. IDE trial, anticipating key milestones in 2024 and 2025.
InspireMD's common stock is listed on the Nasdaq under the ticker symbol NSPR. For more information, visit their website at www.inspiremd.com.
InspireMD, Inc. (NASDAQ: NSPR) announced its participation in the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference, scheduled from September 16-19, 2022, in Boston, MA. The presentation will focus on the CGuard™ Embolic Prevention System and its effectiveness in treating carotid stenosis-related cerebral injury.
Prof. Piotr Musialek will present on September 17, 2022, at 4:15 pm ET. The study aims to provide insights into the clinical application of their technology, which seeks to enhance outcomes in carotid stenting.
InspireMD, Inc. (NASDAQ: NSPR) has partnered with NAMSA for strategic outsourcing to enhance medical device development and commercialization. This collaboration aims to expedite the launch of InspireMD's CGuard™ Embolic Prevention System for carotid artery disease and stroke prevention. Both companies focus on accelerating clinical development through NAMSA's expertise in navigating regulatory requirements. InspireMD plans to leverage this partnership to advance its MicroNet™ technology, aiming to establish it as a standard in the carotid stenting market.
InspireMD reported a 47.8% growth in CGuard™ revenue year-over-year, achieving $1,505,000 in the second quarter of 2022. This surge in sales volume came from selling 2,602 stent systems compared to 1,623 in Q2 2021. Despite the positive revenue growth, the company's net loss widened to $4,636,000 or $0.59 per share, up from $3,507,000, as operating expenses increased significantly. Total revenue for the first half of 2022 reached $2,714,000, marking a 32.8% rise year-over-year.
InspireMD (Nasdaq: NSPR) will report its second quarter 2022 financial results on August 9, 2022, before market opening. The company, known for the CGuard™ Embolic Prevention Stent System, aims to provide significant clinical advancements in treating carotid artery disease. A conference call will occur at 8:30 a.m. EDT on the same day to discuss these results and corporate updates. InspireMD focuses on ensuring long-term stroke-free outcomes through its proprietary MicroNet® technology.
InspireMD, Inc. (Nasdaq: NSPR) appointed endovascular pioneer Dr. Juan Parodi as a strategic advisor on July 14, 2022. Known for performing the first endovascular repair procedure in 1990, Dr. Parodi brings significant expertise to InspireMD's efforts in stroke prevention. CEO Marvin Slosman emphasized Dr. Parodi's contributions to vascular surgery, particularly with the CGuard™ Embolic Prevention System, which aims to enhance patient outcomes in carotid artery disease. Dr. Parodi's involvement underscores InspireMD's commitment to innovation and clinical performance.
InspireMD (Nasdaq: NSPR) showcased its CGuard™ Embolic Prevention System at the LINC 2022 conference, emphasizing its advantages in carotid revascularization. A successful live procedure highlighted CGuard's optimal vessel conformability and MicroNet mesh technology, offering superior patient protection. Results from various studies presented at LINC demonstrated significantly lower rates of death, stroke, and myocardial infarction with CGuard compared to traditional stents, reinforcing its market leadership in stroke prevention.
InspireMD will showcase its CGuard™ Embolic Prevention System (EPS) at the upcoming LINC 2022 conference in Leipzig, Germany, from June 6-9. The live case transmission aims to exhibit the system's ease-of-use and patient safety features. CEO Marvin Slosman highlighted the significance of the event for engaging with the clinical community. Presentations will feature evidence supporting the superiority of CGuard™ EPS over conventional stents. The conference serves as a vital platform for discussing advancements in vascular medicine.
InspireMD reported a 20% increase in CGuard™ revenue, totaling $1,161,000 for Q1 2022. The company completed its first European enrollment in the C-Guardian FDA trial and established a logistics hub with BOMI Group to enhance market access. Despite operating expenses rising by 34.7% to $4,608,000, total revenue grew by 17.6%. However, the net loss increased to $4,481,000, or $0.57 per share. The CEO emphasized ongoing efforts in expanding market share and improving clinical outcomes.
InspireMD (Nasdaq: NSPR) will announce its first quarter 2022 financial results on May 10, 2022, before market opening. A conference call is scheduled for 8:30 a.m. ET the same day to review these results and discuss corporate developments. The call will be accessible via a webcast. InspireMD aims to utilize its MicroNet® technology for improving the outcomes in carotid stenting.
InspireMD, Inc. (Nasdaq: NSPR) has announced a Key Opinion Leader (KOL) webinar on its CGuard™ Embolic Prevention Stent System for treating Carotid Artery Disease and stroke prevention.
The webinar is scheduled for March 22, 2022, at 2 p.m. ET, featuring experts including Chris Metzger, Adnan Siddiqui, and Sean Lyden. They will discuss the unmet needs in the carotid/neurovascular market and how InspireMD's products could fill this gap.
The management team will share insights about leveraging their MicroNet technology to enhance stroke prevention and patient outcomes.
FAQ
What is the current stock price of InspireMD (NSPR)?
What is the market cap of InspireMD (NSPR)?
What does InspireMD, Inc. specialize in?
What are the key products of InspireMD?
Where is InspireMD headquartered?
In which markets does InspireMD operate?
What recent developments have been announced by InspireMD?
Who is the CEO of InspireMD?
What are the financial results for InspireMD in the third quarter of 2023?
What is the trading symbol for InspireMD?
What is the MicroNet technology?